Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.424NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.350NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.496NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.402NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.304NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.590NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.426NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.315NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.162NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.516NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.354NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.116NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FZ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FY.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.571NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JW.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.497NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EN.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.55 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.30 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.85 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.403NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.6.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAMNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FP.2.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.7.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FK.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.1.239NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBFNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.355NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.11.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.574NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.337NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.163NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.607NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.376NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDHNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.356NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.158NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used